Search hospitals > Tennessee > Germantown
GastroOne
Claim this profileGermantown, Tennessee 38138
Global Leader in Crohn's Disease
Global Leader in Ulcerative Colitis
Conducts research for Inflammatory Bowel Disease
Conducts research for Ulcer
Conducts research for Fatty Liver Disease
122 reported clinical trials
2 medical researchers
Summary
GastroOne is a medical facility located in Germantown, Tennessee. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease, Ulcer, Fatty Liver Disease and other specialties. GastroOne is involved with conducting 122 clinical trials across 47 conditions. There are 2 research doctors associated with this hospital, such as Ziad Younes and Scott Duncan, MD.Top PIs
Ziad YounesGastro One6 years of reported clinical research
Studies Colorectal Cancer
Studies Ulcerative Colitis
15 reported clinical trials
16 drugs studied
Scott Duncan, MDGastroOne1 year of reported clinical research
Studies Crohn's Disease
Studies Ulcerative Colitis
2 reported clinical trials
3 drugs studied
Clinical Trials running at GastroOne
Crohn's Disease
Liver Cirrhosis
Cholangitis
Primary Biliary Cirrhosis
Ulcerative Colitis
Fibrosis
Nonalcoholic Steatohepatitis
Sclerosing Cholangitis
Primary Sclerosing Cholangitis
Inflammatory Bowel Disease
Mirikizumab
for Crohn's Disease
This trial is testing mirikizumab to see if it can help people with Crohn's disease feel better over a long time and ensure it is safe. The drug works by reducing gut inflammation.
Recruiting2 awards Phase 3
Risankizumab
for Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely active CD in adult participants. Risankizumab is an approved drug for adults with CD. This study comprises of a Period A and a Period B. In Period A, participants are placed in 1 of 2 groups to receive either risankizumab SC or Placebo. In Period B, based on response, participants will receive risankizumab SC Dose B or Placebo. Participants who do not have improvement in CD symptoms at Week 12 will receive risankizumab SC Dose C and participants with worsening CD symptoms in period B will receive risankizumab SC. Approximately 276 adult participants with a diagnosis of moderately to severely active CD will be enrolled in approximately 250 sites globally. Participants will receive SC induction treatment of risankizumab or matching placebo for up to 24 weeks in Period A and B. The duration of the study will be approximately 49 weeks.
Recruiting1 award Phase 34 criteria
Immunomodulator Strategy
for Inflammatory Bowel Disease
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis \[UC\]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Recruiting1 award N/A
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at GastroOne?
GastroOne is a medical facility located in Germantown, Tennessee. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease, Ulcer, Fatty Liver Disease and other specialties. GastroOne is involved with conducting 122 clinical trials across 47 conditions. There are 2 research doctors associated with this hospital, such as Ziad Younes and Scott Duncan, MD.